The trial met its primary endpoint, demonstrating a statistically significant 77% proptosis response rate at 24 weeks.

Global drug maker Pfizer (PFE) and biotech firm Amgen (AMGN), each valued at over HK$1T ($153B), are among 22 strategic ...

With a market cap of $191.8 billion, Amgen Inc. (AMGN) is a global biotechnology company that discovers, develops, ...

If you are wondering whether Amgen’s recent share price puts it on sale or at a premium, and what that really means for your ...

Amgen's Tepezza became the first drug approved by the FDA for thyroid eye disease (TED) in 2020, and the company is now looking to extend its role with a new, more patient-friendly formulation. The ...

Delve into the pipeline strategy of major biotech Amgen, which is increasingly diversifying its growth engines.

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.71. New data from a mid-stage study of an Amgen obesity drug showed that it ...

Evidence gaps include limited topline safety granularity, unknown long-term follow-up and retreatment rates, and lack of ...

Amgen Inc. (NASDAQ:AMGN) is included among the 10 Healthcare Stocks with Highest Dividends. On April 13, UBS lifted its price ...

Amgen announced 52-week results from a phase 2 trial with its weight-management candidate, MariTide. The results Amgen posted don't appear very competitive with Eli Lilly's weight management drug, ...

With another year of double-digit revenue growth in the books, Amgen’s longtime helmsman Robert Bradway continues to sit ...

China approved Amgen’s tarlatamab for previously treated small cell lung cancer, expanding access to the bispecific immunotherapy. Amgen’s bispecific T-cell engager tarlatamab received regulatory ...